Evaluation of the novel Bruton′s tyrosine kinase (BTK) inhibitor GDC-0853 in chronic lymphocytic leukemia (CLL) with wild type or C481S mutated BTK

Authors :: Rose Mantel
Lisa L. Smith
Jennifer A. Woyach
Amy J. Johnson
Sean D. Reiff
Daphne Guinn
Carolyn Cheney
John C. Byrd
Source :: Journal of Clinical Oncology. 34:7530-7530
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: 7530Background: BTK is an attractive target in CLL. Ibrutinib (IB), a first in class irreversible BTK inhibitor (BTKi), abrogates important survival signals in CLL by proximally blocking multiple p...

Full Text Access

Tools